A efficacy of maintenance intensification therapy by(Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer.
Not Applicable
- Conditions
- non-small non-squamous cell lung cancer
- Registration Number
- JPRN-UMIN000013125
- Lead Sponsor
- Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with active infection 2)Patients with interstitial pneumonia by X ray or CT scan 3)severe complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method